|
|
Line 648: |
Line 648: |
| *[[AKA]] ''pancreatic ductal adenocarcinoma''. | | *[[AKA]] ''pancreatic ductal adenocarcinoma''. |
| *[[AKA]] ''pancreatic adenocarcinoma''. | | *[[AKA]] ''pancreatic adenocarcinoma''. |
| ===General===
| | {{Main|Invasive ductal carcinoma of the pancreas}} |
| *Most common type of pancreatic cancer.<ref name=Ref_WMSP>{{Ref WMSP|237}}</ref>
| |
| *Location: usually in the head ~60%.
| |
| **15% in the body, 5% tail, 20% diffuse (head, body & tail).<ref name=Ref_PBoD950>{{Ref PBoD|950}}</ref>
| |
| *Abysmal prognosis.
| |
| | |
| Risk factors:<ref name=Ref_PCPBoD8_471>{{Ref PCPBoD8|471}}</ref>
| |
| *Smoking (RR ~ 2).
| |
| *Pancreatitis.
| |
| *Family history, esp. BRCA2.
| |
| *[[Diabetes mellitus]] - modest risk increase.
| |
| | |
| Molecular characteristics:<ref name=Ref_PCPBoD8_470-1>{{Ref PCPBoD8|470-1}}</ref><ref name=pmid19896096>{{Cite journal | last1 = Furukawa | first1 = T. | title = Molecular pathology of pancreatic cancer: implications for molecular targeting therapy. | journal = Clin Gastroenterol Hepatol | volume = 7 | issue = 11 Suppl | pages = S35-9 | month = Nov | year = 2009 | doi = 10.1016/j.cgh.2009.07.035 | PMID = 19896096 }}</ref>
| |
| #KRAS (oncogene) mutation in ~ 90% of cases.
| |
| #CDKN2A<ref name=omim600160>{{OMIM|600160}}</ref> ([[AKA]] p16) inactivation ~ 95% of cases.
| |
| #TP53 (AKA p53).
| |
| #SMAD4.
| |
| | |
| ===Microscopic===
| |
| Features:<ref name=Ref_PBoD951>{{Ref PBoD|951}}</ref>
| |
| *Often glandular, may be solid.
| |
| *Nuclei.
| |
| **May be bland - little pleomorphism.
| |
| **Often small nuclei.
| |
| **Sometimes [[coffee-bean nuclei|coffee-bean]] appearance.
| |
| *Cytoplasm - granular, abundant.
| |
| *Quasi endocrine look.
| |
| **May stain positive for endocrine markers.
| |
| | |
| Other features:
| |
| *+/-Necrosis.
| |
| *+/-Myxoid degeneration.
| |
| *+/-Cells around vessels.
| |
| | |
| DDx:
| |
| *[[Chronic pancreatitis]].<ref name=pmid16273946>{{Cite journal | last1 = Adsay | first1 = NV. | last2 = Bandyopadhyay | first2 = S. | last3 = Basturk | first3 = O. | last4 = Othman | first4 = M. | last5 = Cheng | first5 = JD. | last6 = Klöppel | first6 = G. | last7 = Klimstra | first7 = DS. | title = Chronic pancreatitis or pancreatic ductal adenocarcinoma? | journal = Semin Diagn Pathol | volume = 21 | issue = 4 | pages = 268-76 | month = Nov | year = 2004 | doi = | PMID = 16273946 }}</ref>
| |
| *[[Cholangiocarcinoma]].
| |
| | |
| ====Images====
| |
| <gallery>
| |
| Image:Pancreas_adenocarcinoma_(3)_Case_01.jpg | Pancreatic adenocarcinoma (WC)
| |
| Image:Pancreas_adenocarcinoma_(2)_Case_01.jpg | Pancreatic adenocarcinoma (WC)
| |
| Image:Pancreas_neoplasia_carcinoma_sequence.png | Normal pancreas, pancreatic intraepithelial neoplasia and pancreatic carcinoma (WC)
| |
| Image:Pancreas_FNA;_adenocarcinoma_vs._normal_ductal_epithelium_(200x).jpg| Pancreatic adenocarcinoma - cytopathology (WC)
| |
| </gallery>
| |
| www:
| |
| *[http://path.upmc.edu/cases/case384.html Pancreatic adenocarcinoma - several images (upmc.edu)].
| |
| | |
| ===IHC===
| |
| Features:<ref name=Ref_Lester3>{{Ref Lester3|94}}</ref>
| |
| *CD7 +ve.
| |
| *CD20 +ve.
| |
| *SMAD4 -ve ~55% of cases -- stomach usually +ve.
| |
| *CDX2 -ve/+ve.
| |
| *CEA +ve.<ref name=pmid16183479>{{Cite journal | last1 = Adsay | first1 = NV. | last2 = Basturk | first2 = O. | last3 = Cheng | first3 = JD. | last4 = Andea | first4 = AA. | title = Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects. | journal = Semin Radiat Oncol | volume = 15 | issue = 4 | pages = 254-64 | month = Oct | year = 2005 | doi = 10.1016/j.semradonc.2005.04.001 | PMID = 16183479 }}</ref>
| |
| | |
| ===Sign out===
| |
| <pre>
| |
| MASS, PANCREAS, CORE BIOPSY:
| |
| - ADENOCARCINOMA, MODERATELY DIFFERENTIATED.
| |
| </pre>
| |
| | |
| Note:
| |
| *On biopsy, it isn't easy to separate from [[cholangiocarcinoma]]. Thus, it is better to stay vague.
| |
|
| |
|
| ==Pancreatic neuroendocrine tumour== | | ==Pancreatic neuroendocrine tumour== |